| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Pfizer Inc. | TUKYSA, trastuzumab, and pertuzumab - (HER2CLIMB-05) | HER2+ Metastatic Breast Cancer | PDUFA | Data Released | Oral Intravenous Intravenous | Oncology |
| Pfizer Inc. | KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) | Muscle-invasive bladder cancer (MIBC) | PDUFA | Data Released | Intravenous | Oncology |
| Pfizer Inc. | KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) - (KEYNOTE-B15/EV-304) | Muscle-invasive bladder cancer (MIBC) | PDUFA | Data Released | Intravenous | Oncology |
| Pfizer Inc. | TUKYSA, trastuzumab, and pertuzumab - (HER2CLIMB-05) | HER2+ Metastatic Breast Cancer | PDUFA | Data Released | Oral Intravenous Intravenous | Oncology |
| Pfizer Inc. | Vepdegestrant (ARV-471) - (VERITAC-2) | Breast cancer | PDUFA | Ongoing | Oral | Oncology |
| Pfizer Inc. | Samuraciclib (CT7001) and vepdegestrant (ARV-471) | ER+, HER2- metastatic breast cancer | PDUFA | Ongoing | Oral | Oncology |
| Pfizer Inc. | MYFEMBREE (relugolix, estradiol and norethindrone acetate) | Heavy menstrual bleeding associated with uterine fibroids | BLA Filing | Oral | Women's Health | |
| Pfizer Inc. | Relugolix (combination) - (SPIRIT) | Endometriosis | sNDA Filing | Oral | Women's Health |